CHRS
Coherus Oncology, Inc.
CHRS's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CHRS overall, supported by stronger fundamentals and lower modeled downside.
CHRS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
CHRS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CHRS PE Valuation
CHRS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CHRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect CHRS's losses to shrink, with revenue growing.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CHRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.00 | -172% |
| Q2 2026 | -$1.06 | -166% |
| Q1 2026 | $1.64 | +$2.71 |
| Q4 2025 | $1.43 | +472% |
| Q3 2025 | $1.39 | +$1.43 |
| Q2 2025 | $1.61 | +$1.97 |
| Q1 2025 | -$1.07 | -$0.33 |
| Q4 2024 | $0.25 | +$2.78 |
CHRS has swung to a loss: it lost $1.00 per share over the past year, after a profit the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CHRS on earnings quality, reporting a profit while its opponent remains loss making.
CHRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14.3M | +23% |
| Q2 2026 | $14.3M | +40% |
| Q1 2026 | $12.3M | +62% |
| Q4 2025 | $12.7M | -76% |
| Q3 2025 | $11.6M | -84% |
| Q2 2025 | $10.3M | -84% |
| Q1 2025 | $7.6M | -90% |
| Q4 2024 | $54.1M | -41% |
CHRS's revenue is recovering but still below its 2020 peak: $14M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -236% | +147 points |
| Q2 2026 | -226% | +218 points |
| Q1 2026 | -294% | +304 points |
| Q4 2025 | -360% | -282 points |
| Q3 2025 | -383% | -374 points |
| Q2 2025 | -444% | -412 points |
| Q1 2025 | -598% | -543 points |
| Q4 2024 | -78% | -2.7 points |
CHRS's operating margin was −236% last quarter, up 147 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CHRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CHRS on profitability, with a higher operating margin.
CHRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34M | +$12.3M |
| Q2 2026 | -$62.1M | -$15.5M |
| Q1 2026 | -$57.9M | -$32.1M |
| Q4 2025 | -$19.7M | -169% |
| Q3 2025 | -$46.3M | +$15.7M |
| Q2 2025 | -$46.6M | -178% |
| Q1 2025 | -$25.8M | +$20.9M |
| Q4 2024 | $28.6M | +$41.6M |
CHRS has burned cash in most quarters: −$174M over the past year, against −$90M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CHRS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CHRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +154K shares |
| 1 year | +34% | +38.9M shares |
| 3 years | +78% | +67.7M shares |
| 5 years | +105% | +79.4M shares |
| Available history | +112% | +81.8M shares |
CHRS has 155M diluted shares, up 34% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CHRS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CHRS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | -2.9x | Net Cash |
| Q3 2020 | -1.1x | Net Cash |
| Q2 2020 | -0.7x | Net Cash |
| Q1 2020 | -0.7x | Net Cash |
| Q4 2019 | -0.9x | Net Cash |
CHRS has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CHRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 3.7 | Oversold |
CHRS's weekly RSI is 24 (oversold) and its Stochastic is 4 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CHRS PE vs Healthcare Sector
| Metric | CHRS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CHRS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CHRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.94 | 43% below |
| 20 week MA | $1.21 | 55% below |
| 50 week MA | $1.46 | 63% below |
| 100 week MA | $1.30 | 58% below |
| 200 week MA | $2.34 | 77% below |
CHRS is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CHRS on trend strength, trading above more of its moving averages.
CHRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $17.4 | -4.7% |
| 2021 | $17.4 | $17.8 | +2.5% |
| 2022 | $17.8 | $6.45 | -64% |
| 2023 | $6.45 | $3.33 | -48% |
| 2024 | $3.33 | $1.49 | -55% |
| 2025 | $1.49 | $1.33 | -11% |
| 2026 YTD | $1.33 | $0.54 | -59% |
CHRS has finished four years in a row lower, and it's down 59% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CHRS on returns for 2026, with the stronger performance.